ORGANOVO HOLDINGS INC (ONVO)

Company Profile

Organovo Holdings, Inc. is engaged in the development of bioprinted human tissues that emulate human biology and disease. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2013-08-02. The firm is focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues, as well as preclinical data. Its segments include research and development (R&D) and Mosaic Cell Sciences (Mosaic). The company is also focused on building high fidelity, 3D tissues that recapitulate key aspects of human disease. The company uses its proprietary technology to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. Its Mosaic division to serve as a key source of certain primary human cells it utilizes in its research and development efforts. Its 3D human tissue platform is multifaceted. Its NovoGen Bioprinters can also dispense pure hydrogel formulations, provided the physical properties of the hydrogel are compatible with the dispensing parameters.

Company Info

ORGANOVO HOLDINGS INC

Suite 100, 11555 Sorrento Valley Road

San Diego CALIFORNIA 92075

P: 18582241000

CEO: Keith Murphy

Employees: 20

Website: https://organovo.com/